Condition: Spinal Muscular Atrophy (SMA) · Charcot-Marie-Tooth · Muscular Dystrophy · Sponsor: Institut de Myologie, France
In recent years, knowledge of neuromuscular diseases has advanced considerably, and new therapeutic avenues are beginning to emerge. The proliferation of clinical trials has created a need to identify biomarkers that are both sensitive to changes and specific to the disease. Current gait tests only consider the time factor and not the evolution of the patient's biomechanics, which may prove insufficient for patients whose symptoms generally progress slowly. Quantifying gait parameters in neuromuscular patients therefore appears necessary. This is why we propose to study markerless gait analysis in this population, which would allow for simple and effective monitoring of kinematic parameters without resorting to complex equipment incompatible with routine clinical practice.
This description comes directly from the study's public registry record.
Pauline SANTMARTY, MsC · +33 01 42 16 58 79 · p.santmarty@institut-myologie.org
Romain FEIGEAN, PhD · +33 142166649 · r.feigean@institut-myologie.org
Always discuss trial participation with your own doctor first.
| Centre d'Exploration et d'Évaluation Neuromusculaire | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07321977